Amycretin vs Tirzepatide
Comparing Novo Nordisk's next-generation GLP-1/amylin unimolecular agonist amycretin with Eli Lilly's dual GIP/GLP-1 agonist tirzepatide.
Last updated: February 1, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Amycretin
Dossier overview
Tirzepatide
Dossier overview
Overview
Amycretin and tirzepatide represent competing dual-agonist strategies for obesity. Amycretin combines GLP-1 with amylin receptor activity in a single molecule, while tirzepatide combines GLP-1 with GIP receptor activity. Both aim for superior weight loss versus GLP-1-only approaches, but through different secondary mechanisms.
Mechanism Comparison
| Aspect | Amycretin | Tirzepatide |
|---|---|---|
| Primary Target | GLP-1 receptor | GLP-1 receptor |
| Secondary Target | Amylin receptors | GIP receptor |
| Molecule Design | Unimolecular dual agonist | Single dual agonist |
| Satiety Pathways | Hypothalamus + brainstem | Hypothalamus |
Different Companion Mechanisms
Amycretin (GLP-1 + Amylin):
- Amylin signals meal completion
- Area postrema activation
- Complementary to GLP-1’s hypothalamic effects
- Same rationale as CagriSema
Tirzepatide (GLP-1 + GIP):
- GIP enhances insulin secretion
- Central effects on satiety
- Metabolic benefits beyond GLP-1
- Proven in clinical trials
Evidence Comparison
| Aspect | Amycretin | Tirzepatide |
|---|---|---|
| Development Phase | Phase 1/2 | FDA Approved |
| Human Data | Conference presentations | Extensive published |
| Regulatory Status | Early investigational | Approved (2022) |
| Real-world Data | None | Accumulating |
Efficacy Data
Amycretin (Phase 1 - Early Data)
| Timeframe | Weight Loss |
|---|---|
| 12 weeks | ~13% |
| Projected annualized | ~25% (speculative) |
Caveats: Small sample, short duration, extrapolation unreliable.
Tirzepatide (SURMOUNT-1)
| Dose | Weight Loss (72 weeks) |
|---|---|
| 5mg | ~15% |
| 10mg | ~19.5% |
| 15mg | ~22.5% |
Context: Phase 3 data with large sample sizes and long duration.
Regulatory Status
| Aspect | Amycretin | Tirzepatide |
|---|---|---|
| FDA Status | Investigational | Approved |
| Phase | 1/2 | Marketed |
| Indications | TBD | T2D, Obesity |
| Brand Names | N/A | Mounjaro, Zepbound |
| Approval Timeline | 2027+ (optimistic) | Already approved |
Development Timeline Gap
| Milestone | Amycretin | Tirzepatide |
|---|---|---|
| Phase 3 start | Not yet | Completed |
| NDA filing | Years away | 2022 (approved) |
| Market entry | 2027+ | 2022 |
| First-mover advantage | No | Yes |
Side Effect Profile
| Effect | Amycretin (Early) | Tirzepatide |
|---|---|---|
| Nausea | Common | Common |
| Vomiting | Common | Common |
| GI tolerability | Being characterized | Well-understood |
| Discontinuation | TBD | ~5-7% |
Strategic Context
Novo Nordisk Pipeline Position
| Compound | Status | Timeline |
|---|---|---|
| Semaglutide | Approved | Now |
| CagriSema | Phase 3 | 2025-2026 |
| Amycretin | Phase 1/2 | 2027+ |
Amycretin is the next-generation backup if CagriSema succeeds.
The Competitive Challenge
| Factor | Amycretin | Tirzepatide |
|---|---|---|
| Time to market | Years behind | Already available |
| Data maturity | Early | Extensive |
| Manufacturing | In development | Scaled (with shortages) |
| Physician familiarity | None | Growing |
Key Differences
| Factor | Amycretin | Tirzepatide |
|---|---|---|
| Secondary mechanism | Amylin | GIP |
| Brain targets | Hypothalamus + brainstem | Primarily hypothalamus |
| Evidence level | Phase 1 | Phase 3 + approved |
| Availability | Years away | Now |
| Developer | Novo Nordisk | Eli Lilly |
Potential Amycretin Advantages (Theoretical)
If amycretin delivers on early promise:
- Single injection combining GLP-1 + amylin
- Potentially >25% weight loss
- Different mechanism may benefit GIP non-responders
- Could be next-generation leader
But: This requires successful Phase 3 trials years from now.
Summary
- Amycretin shows promising early data (~13% at 12 weeks) but is years from potential approval
- Tirzepatide is the approved benchmark with ~22% weight loss and extensive safety data
- Different secondary mechanisms (amylin vs GIP) represent distinct approaches
- Tirzepatide’s first-mover advantage is substantial
- Amycretin represents Novo’s long-term competitive strategy
This comparison is for educational purposes only. Amycretin is in early-stage investigation. Consult a healthcare provider for treatment decisions.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.